Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase

被引:21
|
作者
Awoonor-Williams, Ernest [1 ,2 ]
Rowley, Christopher N. [3 ]
机构
[1] Mem Univ Newfoundland, Dept Chem, St John, NF A1B 3X9, Canada
[2] Novartis Inst BioMed Res, 181 Massachusetts Ave, Cambridge, MA 02139 USA
[3] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
FREE-ENERGY CALCULATIONS; PROTEIN-KINASES; DRUG DISCOVERY; SIDE-CHAINS; GLEEVEC; SELECTIVITY; MODIFIERS; POTENCY; DESIGN; ABL;
D O I
10.1021/acs.jcim.1c00897
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeted covalent inhibitors (TCIs) bind to their targets in both covalent and noncovalent modes, providing exceptionally high affinity and selectivity. These inhibitors have been effectively employed as inhibitors of protein kinases, with Taunton and coworkers (Nat. Chem. Biol. 2015, 11, 525-531) reporting a notable example of a TCI with a cyanoacrylamide warhead that forms a covalent thioether linkage to an active-site cysteine (Cys481) of Bruton's tyrosine kinase (BTK). The specific mechanism of the binding and the relative importance of the covalent and noncovalent interactions is difficult to determine experimentally, and established simulation methods for calculating the absolute binding affinity of an inhibitor cannot describe the covalent bond-forming steps. Here, an integrated approach using alchemical free-energy perturbation and QM/MM molecular dynamics methods was employed to model the complete Gibbs energy profile for the covalent inhibition of BTK by a cyanoacrylamide TCI. These calculations provide a rigorous and complete absolute Gibbs energy profile of the covalent modification binding process. Following a classic thiol-Michael addition mechanism, the target cysteine is deprotonated to form a nucleophilic thiolate, which then undergoes a facile conjugate addition to the electrophilic functional group to form a bond with the noncovalently bound ligand. This model predicts that the formation of the covalent linkage is highly exergonic relative to the noncovalent binding alone. Nevertheless, noncovalent interactions between the ligand and individual amino acid residues in the binding pocket of the enzyme are also essential for ligand binding, particularly van der Waals dispersion forces, which have a larger contribution to the binding energy than the covalent component in absolute terms. This model also shows that the mechanism of covalent modification of a protein occurs through a complex series of steps and that entropy, conformational flexibility, noncovalent interactions, and the formation of covalent linkage are all significant factors in the ultimate binding affinity of a covalent drug to its target.
引用
收藏
页码:5234 / 5242
页数:9
相关论文
共 50 条
  • [1] Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
    Davids, Matthew S.
    Brown, Jennifer R.
    FUTURE ONCOLOGY, 2014, 10 (06) : 957 - 967
  • [2] PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding
    Tinworth, Christopher P.
    Lithgow, Hannah
    Dittus, Lars
    Bassi, Zuni I.
    Hughes, Sophie E.
    Muelbaier, Marcel
    Dai, Han
    Smith, Ian E. D.
    Kerr, William J.
    Burley, Glenn A.
    Bantscheff, Marcus
    Harling, John D.
    ACS CHEMICAL BIOLOGY, 2019, 14 (03) : 342 - 347
  • [3] Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
    Tichenor, Mark S.
    Wiener, John J. M.
    Rao, Navin L.
    Bacani, Genesis M.
    Wei, Jianmei
    Deckhut, Charlotte Pooley
    Barbay, J. Kent
    Kreutter, Kevin D.
    Chang, Leon
    Clancy, Kathleen W.
    Murrey, Heather E.
    Wang, Weixue
    Ahn, Kay
    Huber, Michael
    Rex, Elizabeth
    Coe, Kevin J.
    Wu, Jiejun
    Rui, Haopeng
    Sepassi, Kia
    Gaudiano, Marcello
    Bekkers, Mariette
    Cornelissen, Ivo
    Packman, Kathryn
    Seierstad, Mark
    Xiouras, Christos
    Bembenek, Scott D.
    Alexander, Richard
    Milligan, Cynthia
    Balasubramanian, Sriram
    Lebsack, Alec D.
    Venable, Jennifer D.
    Philippar, Ulrike
    Edwards, James P.
    Hirst, Gavin
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (21) : 14326 - 14336
  • [4] Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
    Voice, Angus T.
    Tresadern, Gary
    Twidale, Rebecca M.
    van Vlijmen, Herman
    Mulholland, Adrian J.
    CHEMICAL SCIENCE, 2021, 12 (15) : 5511 - 5516
  • [5] Targeted selective degradation of Bruton's tyrosine kinase by PROTACs
    Liu, Shaodong
    Da, Yang
    Wang, Feng
    Yan, Renjie
    Shu, Yongzhi
    Lin, Pei
    Lin, Jun
    MEDICINAL CHEMISTRY RESEARCH, 2020, 29 (04) : 802 - 808
  • [6] HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development
    Huang, Wenhai
    Wang, Shu
    Zhang, Zhimin
    Zhang, Chixiao
    Zeng, Shenxin
    Liang, Meihao
    Shen, Zhengrong
    Liu, Xingguo
    BIOORGANIC CHEMISTRY, 2020, 105
  • [7] Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
    Shaodong Liu
    Yang Da
    Feng Wang
    Renjie Yan
    Yongzhi Shu
    Pei Lin
    Jun Lin
    Medicinal Chemistry Research, 2020, 29 : 802 - 808
  • [8] Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase
    Harris, Christopher M.
    Foley, Sage E.
    Goedken, Eric R.
    Michalak, Mark
    Murdock, Sara
    Wilson, Noel S.
    SLAS DISCOVERY, 2018, 23 (10) : 1040 - 1050
  • [9] Targeted covalent-reversible inhibitors for the treatment of autoimmune and inflammatory disease: Application to Bruton's tyrosine kinase
    Schnute, Mark
    Springer, John
    Selness, Shaun
    Hughes, Robert
    Ohren, Jeff
    Caspers, Nicole
    Han, Seungil
    Huang, Nelson
    Geoghegan, Kieran
    Xing, Li
    Grapperhaus, Margaret
    Owen, Thomas
    Schmidt, Michelle
    Devadas, Balekudru
    Hockerman, Susan
    Rogier, D. Joseph
    Zapf, Christoph
    Hotchandani, Rajeev
    Wu, Yuchuan
    Buchler, Ingrid
    Kim, Kyung-Hee
    Huang, Adrian
    Chenail, Eva
    Saiah, Eddine
    Wan, Zhao-Kui
    Trujillo, John
    Parikh, Mihir
    Wittwer, Arthur
    Li, Evelyn
    Liu, Erica
    McCarthy, Erin
    Miyashiro, Joy
    Mohan, Shashi
    Wood, Nancy
    Edmonds, Jason
    Miao, Wenyan
    Seth, Nilufer
    Beidler, David
    Singh, Pratap
    Messing, Dean
    Soucy, Sarah
    Wrocklage, Christopher
    Andrey, Tatyana
    Rankin, Andrew
    Hegen, Martin
    Nutter, Cheryl
    Douhan, John
    Dunussi-Joannopoulos, Kyri
    Thaisrivongs, Suvit
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [10] Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
    Woyach, Jennifer A.
    Furman, Richard R.
    Liu, Ta-Ming
    Ozer, Hatice Gulcin
    Zapatka, Marc
    Ruppert, Amy S.
    Xue, Ling
    Li, Daniel Hsieh-Hsin
    Steggerda, Susanne M.
    Versele, Matthias
    Dave, Sandeep S.
    Zhang, Jenny
    Yilmaz, Ayse Selen
    Jaglowski, Samantha M.
    Blum, Kristie A.
    Lozanski, Arletta
    Lozanski, Gerard
    James, Danelle F.
    Barrientos, Jacqueline C.
    Lichter, Peter
    Stilgenbauer, Stephan
    Buggy, Joseph J.
    Chang, Betty Y.
    Johnson, Amy J.
    Byrd, John C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24): : 2286 - 2294